Timing of 17-Hydroxyprogesterone Blood Draw
Draw 17-hydroxyprogesterone in the early morning (ideally between 0700-0900h) before the morning dose of hydrocortisone in patients being monitored for congenital adrenal hyperplasia.
Rationale for Morning Timing
17-OHP demonstrates marked circadian variation with peak levels occurring between 0400-0900h 1, 2, 3. This physiologic pattern is critical for accurate interpretation:
- Peak morning levels: 17-OHP concentrations are highest in the early morning hours, making this the most sensitive time to detect inadequate adrenal suppression
- Evening suppression: Levels drop to approximately 40% of morning values by evening 4, which can mask poor control if sampled at the wrong time
- Pre-dose timing: Blood should be drawn before the morning hydrocortisone dose to assess the nadir of therapeutic suppression 1
Clinical Context Matters
The timing recommendation differs based on the clinical scenario:
For CAH Monitoring (Most Common Context)
- Optimal time: 0700-0900h before morning hydrocortisone dose 1
- Complementary testing: Include androstenedione measurement simultaneously, as it correlates strongly with integrated 17-OHP levels (r=0.81) 1
- Important caveat: Single 17-OHP values provide limited information about treatment adequacy 2. The extreme fluctuations mean one value may not reflect overall control
For Newborn Screening
- Timing consideration: Avoid testing in the first 2 days of life when diagnostic accuracy is poor 5
- Gestational age matters: 17-OHP levels are normally elevated at birth and decrease rapidly in the first postnatal days, while they increase over time in affected infants 5
- Retest requirement: Infants exposed to antenatal corticosteroids should be retested after several days of life 5
Common Pitfalls to Avoid
- Random timing: Drawing 17-OHP at variable times of day makes serial comparisons meaningless due to circadian variation
- Post-dose sampling: Cortisol rises rapidly after hydrocortisone administration, causing steep falls in 17-OHP within 60 minutes 2, which artificially suggests good control
- Over-reliance on single values: 17-OHP shows extreme fluctuations; clinical assessment based on growth and pubertal progress remains primary 1
- Assuming suppressed = overtreated: Suppressed 17-OHP levels do not always indicate overtreatment 6
Alternative Monitoring Approaches
While serial 4-hour 17-OHP profiles have been studied 6, they do not reliably predict hyperandrogenemia and are not worth the effort for routine monitoring. The strong correlation between baseline and subsequent time points (r=0.929-0.943) 6 confirms that a single well-timed morning sample is sufficient.
Note: The evidence provided regarding 17-alpha hydroxyprogesterone caproate 7, 8, 9 relates to a different compound used in obstetrics and is not relevant to this question about 17-hydroxyprogesterone testing for CAH.